首页> 外文期刊>Diabetology and Metabolic Syndrome >Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes
【24h】

Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes

机译:在患有糖尿病和无糖尿病的高血压患者队列中,他汀类药物的使用与较差的血糖控制有关

获取原文
           

摘要

Background The US Federal and Drug Administration (FDA) recently revised statin drug labels to include the information that increases in fasting serum glucose and glycated haemoglobin levels have been reported with the use of statins. Yet in a survey, 87% of the doctors stated that they had never or infrequently observed increases in glucose or HbA1c levels in patients on statin. In this study we would like to determine the association between the use of statins and glycaemic control in a retrospective cohort of patients with hypertension. Methods A retrospective review of 1060 medical records of patients with hypertension at a primary care clinic was conducted. These records were selected using systematic random sampling (1:4). Data on patient socio-demographic factors; clinical profile; investigation results and prescribed medications were collected. Independent t-test was used for continuous variables while Pearson’s χ2 test was used for categorical variables. Logistic regression was done to adjust for confounders. Results 810 (76.4%) patients with hypertension were on statins, out of which 792 (97.8%) were taking simvastatin 10 mg or 20 mg daily. Analysis of the whole group regardless of diabetes status showed that the statin user group had higher HbA1c and fasting blood glucose values. The difference in HbA1c levels remained significant (adjusted OR?=?1.290, p?=?0.044, 95% CI 1.006, 1.654) after adjustment for diabetes, diabetic medication and fasting blood glucose. In the study population who had diabetes, statin users again had significantly higher HbA1c level compared to statin non-users. This difference remained significant (adjusted OR 1.208, p?=?0.037, 95% CI 1.012, 1.441) after adjustment for age and diabetic medications. Conclusions Statins use is associated with increased HbA1c levels among hypertensive patients and hypertensive patients with diabetes. Clinicians managing hypertensive patients on statins should consider monitoring the HbA1c level and ensure that those with diabetes have their hyperglycaemia kept under control.
机译:背景技术美国联邦药品管理局(FDA)最近修订了他汀类药物的标签,以包括已报道使用他汀类药物会导致空腹血糖升高和糖化血红蛋白水平升高的信息。然而,在一项调查中,有87%的医生表示他们从未或很少观察到他汀类药物患者的血糖或HbA1c水平升高。在这项研究中,我们想确定他汀类药物的使用与高血压患者回顾性队列研究之间的关联。方法回顾性回顾了基层医疗机构对1060例高血压患者的病历。这些记录是使用系统随机抽样(1:4)选择的。有关患者社会人口统计学因素的数据;临床资料;调查结果和处方药被收集。独立t检验用于连续变量,而Pearson的χ2检验用于分类变量。进行逻辑回归以适应混杂因素。结果810名(76.4%)高血压患者使用他汀类药物,其中792(97.8%)名患者每天服用辛伐他汀10 mg或20 mg。不管糖尿病状态如何,对整个组进行分析后发现,他汀类药物使用者组具有较高的HbA1c和空腹血糖值。在调整了糖尿病,糖尿病药物和空腹血糖后,HbA1c水平的差异仍然很显着(校正后的OR?=?1.290,p?=?0.044,95%CI 1.006,1.654)。在患有糖尿病的研究人群中,他汀类药物使用者的HbA1c水平再次高于非他汀类药物。调整年龄和糖尿病药物后,这种差异仍然很显着(校正后的OR 1.208,p?=?0.037,95%CI 1.012,1.441)。结论在高血压和糖尿病高血压患者中,他汀类药物的使用与HbA1c水平升高有关。使用他汀类药物治疗高血压患者的临床医生应考虑监测HbA1c水平,并确保糖尿病患者的高血糖得到控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号